Applied BioCode 

TWD27.15
0
+TWD0.05+0.18% Friday 05:22

統計

當日最高
27.15
當日最低
27.15
52週高點
31.2
52週低點
22.75
成交量
1,000
平均成交量
-
市值
2.79B
本益比
-
股息殖利率
-
股息
-

即將到來

財報

5Nov預期
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q2 2026
下一步
-0.49
-0.43
-0.37
-0.32
預期EPS
不適用
實際EPS
不適用

財務

-42.34%利潤率
未盈利
2020
2021
2022
2023
2024
2025
475.2M營收
-201.2M淨利

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Applied BioCode Corporation specializes in the complete lifecycle—from design and development to manufacturing and commercialization—of multiplex diagnostic testing solutions tailored for the In-Vitro Diagnostics (IVD) market. Among its key offerings are two sophisticated systems: the BioCode MDx 3000, an automated molecular diagnostics platform that streamlines PCR amplification, hybridization, and detection steps; and the BioCode 2500 analyzer, specifically engineered to read barcoded magnetic beads (BMBs) and display their unique identification along with fluorescence intensity. The company also boasts an extensive portfolio of diagnostic assays, including the BioCode SARS-CoV-2 Assay, a high-throughput, automated nucleic acid multiplex test for detecting SARS-CoV-2 genetic material in nasopharyngeal swabs. Other panels comprise BioCode Respiratory Pathogen Panels, capable of simultaneously identifying and differentiating seventeen distinct respiratory pathogens in nasopharyngeal samples, and BioCode gastrointestinal (GI) pathogen panels, which target prevalent GI pathogens such as viruses, bacteria, and parasites responsible for infectious diarrheal diseases. An expanding pipeline of MDx assays for various molecular tests is also under development. Beyond these, Applied BioCode provides specialized reagents like analyte-specific reagents for fungal pathogens, and multiplex kits for human cytokines and chemokines, vital for biomarker identification. For research flexibility, they offer premixed and customizable multiplex kits for mouse models, alongside similar cytokine/chemokine multiplex kits for rat, monkey, canine, and non-human primate studies. Rounding out its comprehensive services, the company supplies its proprietary BMBs, calibration beads, and coupling kits for a wide array of bioassay applications. They also offer ELISA (Enzyme-Linked Immunosorbent Assay), a method for the precise quantification of drug, protein, or antibody levels in biological samples such as cell lysates or serum, in addition to providing full-spectrum assay development services. Applied BioCode Corporation is headquartered in Santa Fe Springs, California.
Show more...
執行長
Winston Z.
員工
43
國家
開曼群島
ISIN
KYG0488D1051

上市

0 Comments

分享你的想法

FAQ

Applied BioCode 今天的股價是多少?
6598.TWO 目前價格為 TWD27.15 TWD,過去 24 小時上漲了 +0.18%。在圖表上更密切關注 Applied BioCode 股價表現。
Applied BioCode 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 Taiwan OTC Exchange 交易所,Applied BioCode 的股票以代號 6598.TWO 進行交易。
Applied BioCode 的市值是多少?
今天 Applied BioCode 的市值為 2.79B
Applied BioCode 下一次財報日期是什麼時候?
Applied BioCode 將於 November 05, 2026 公布下一次財報。
Applied BioCode 去年的營收是多少?
Applied BioCode 去年的營收為 475.2MTWD。
Applied BioCode 去年的淨利是多少?
6598.TWO 去年的淨收益為 -201.2MTWD。
Applied BioCode 有多少名員工?
截至 September 05, 2026,公司共有 43 名員工。
Applied BioCode 位於哪個產業?
Applied BioCode從事於Health & Wellness產業。
Applied BioCode 何時完成拆股?
Applied BioCode 最近沒有進行任何拆股。
Applied BioCode 的總部在哪裡?
Applied BioCode 的總部位於 開曼群島 的 Grand Cayman。